Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch).

News
Trevi Therapeutics to Present at the Annual Cowen and Company Healthcare Conference
2/23/2015
Trevi Therapeutics Closes $15 Million Debt Facility Provided by Solar Capital and Square 1 Bank
1/8/2015
Trevi Therapeutics to Present at the J.P. Morgan Healthcare Conference
1/5/2015